The solid tumor testing market will grow to $46.7 billion by 2031:

The solid tumor testing market will grow to .7 billion by 2031:

Portland, OR, November 9, 2022 (GLOBE NEWSWIRE) — A new business intelligence report released by Allied Market Research, the Solid Tumor Testing Market it earned $23.8 billion in 2021 and is estimated to generate $46.7 billion by 2031, manifesting a CAGR of 7.0% from 2022 to 2031. The report provides an extensive analysis of the changing dynamics of the market, the main segments, the value chain, the competitive scenario and the regional panorama. . This research offers valuable guidance for major players, investors, shareholders, and startups in designing strategies for sustainable growth and gaining competitive advantage in the marketplace.

Download free sample report:

Coverage and details of the report:

Report Coverage Details
forecast period 2022-2031
base year 2021
Market size in 2021 $23.8 billion
Market size in 2031 $46.7 billion
CAGR 7.0%
No. of pages in the report 225
Covered segments Type, Application, End User, and Region.
drivers Increase in geriatric population prone to solid tumors
Increased prevalence of bladder tumors, prostate tumors, breast tumors, colorectal tumors, endometrial tumors, lung tumors, melanoma tumors, brain tumor, thyroid tumor, liver tumor, and ovarian tumor
Increasing demand for the minimally invasive procedure for the diagnosis of solid tumors worldwide
Increased unhealthy lifestyles, eg increased smoking, alcohol use
Increased use of supplements and steroids
Opportunities Technological advances
Strategies between key players such as acquisition, collaboration and agreement.
restrictions expensive tests

Covid-19 scenario:

  • The outbreak of the COVID-19 pandemic had a negative impact on the growth of the global solid tumor testing market as a large number of medical schools and hospitals around the world were rebuilt to increase hospital capacity for diagnosed patients. with COVID-19.
  • The pandemic has negatively altered the way cancer patients are diagnosed and treated in the short term. For example, according to a National Library of Medicine review article published in 2020, it is estimated that as a result of COVID-19, breast, colon, and cervical cancer screenings have dropped by 94%, 86%, and 94% between January 20, 2020 and April 21, 2020, respectively.

The research provides detailed segmentation of the global Solid Tumor Testing market on the basis of type, application, end user and region. The report analyzes the segments and their sub-segments in detail with the help of tables and figures. Market players and investors can strategize according to the fastest growing and highest revenue generating segments mentioned in the report.

Purchase consultation:

Based on type, the genetic testing segment had the highest share in 2021, accounting for nearly two-thirds of the global solid tumor testing market, and is expected to continue its leading status during the forecast period. Furthermore, the same segment is expected to record the highest CAGR of 7.3% from 2022 to 2031.

Based on the application, the melanoma segment accounted for the highest share in 2021, contributing nearly a fifth of the global solid tumor testing market, and is expected to maintain its leadership in terms of revenue over the forecast period. However, the breast segment is expected to post the highest CAGR of 7.7% between 2022 and 2031.

According to end-user, the hospital segment accounted for the highest share in 2021, with nearly a third of the global solid tumor testing market, and is expected to continue its leading status over the forecast period. However, the academic research institutions segment is estimated to grow at the highest CAGR of 7.2% during the forecast period.

Based on region, North America had the largest share in 2021, contributing around two-fifths of the global solid tumor testing market share, and is projected to maintain its dominant share in terms of revenue in 2031 Furthermore, Asia-Pacific region is expected to manifest the fastest CAGR of 8.3% during the forecast period. The research also looks at regions such as Europe and LAMEA.

Major players in the global solid tumor testing market analyzed in the research include QIAGEN, QUEST DIAGNOSTICS INCORPORATED, Abbott Laboratories, Agilent Technologies Inc., Biocare Medical LLC, F. Hoffmann-La Roche AG, ILLUMINA, INC., MedGenome Labs Private Ltd., MYRIAD GENETICS, INC., Thermo Fisher Scientific, Inc.

The report provides detailed analysis of these key players of the global Solid Tumor Testing market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting the business performance, operating segments, product portfolio, and strategic moves of market players to show the competitive landscape.

Reports of trends in the health industry (Book now with a 10% discount):

Women’s Health Diagnostic Market By Type (Diagnostic Devices, Diagnostic Tests, Accessories and Consumables), By End User (Hospitals and Clinics, Diagnostic and Imaging Centers, Home Care, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

IVF Devices and Consumables Market by product (instruments, accessories and disposables, and reagents and media), type of technology (IVF fresh embryos, IVF frozen embryos and IVF donor eggs) and end user (fertility clinics, hospitals, surgical centers and institutes of Clinical Research): Global Opportunity Analysis and Industry Forecast, 2021-2030

Fertility Services Market by Procedure (IVF with ICSI, IUI, IVF without ICSI, Surrogacy and Others), Service (Fresh without donor, Frozen without donor, Egg and Embryo Bank, Fresh Donor and Frozen Donor) and End User (Fertility clinics, hospitals , Surgical Centers and Clinical Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020-2030

Rapid test market by Product (Over-the-Counter Rapid Test, Professional Rapid Test and Others), Application (Infectious Diseases, Cardiology, Oncology, Pregnancy, Infertility, Toxicology, Glucose Monitoring and Others) and End User (Hospitals and Clinics, Home Care, Health Center). Diagnosis and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

Optical Imaging Market by product type (imaging systems, lighting systems, camera, software and lenses), therapeutic area (ophthalmology, oncology, cardiology, neurology and others) and end user (hospitals and clinics, research laboratories and pharmaceutical and biotechnology companies ) : Global Opportunity Analysis and Industry Forecast, 2021-2030

About us

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP headquartered in Portland, Oregon. Allied Market Research provides global companies, as well as small and medium-sized businesses, with an unmatched quality of “Market research reports” and “Business Intelligence Solutions”. AMR has a specific vision to provide business insights and consulting to help its clients make strategic business decisions and achieve sustainable growth in their respective market domain.

We maintain professional corporate relationships with various companies and this helps us extract market data that helps us generate accurate research data tables and confirms the utmost accuracy in our market forecast. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high data quality and assist clients in every way possible to achieve success. Each and every one of the data presented in the reports published by us is extracted through primary interviews with senior officials of the main companies of the domain in question. Our secondary data acquisition methodology includes in-depth online and offline research and discussions with industry professionals and expert analysts.


Leave a Comment